| Literature DB >> 24688797 |
Mohammad Mahdi Moein1, Rana Said2, Fatma Bassyouni3, Mohamed Abdel-Rehim4.
Abstract
In drug discovery and development, the quantification of drugs in biological samples is an important task for the determination of the physiological performance of the investigated drugs. After sampling, the next step in the analytical process is sample preparation. Because of the low concentration levels of drug in plasma and the variety of the metabolites, the selected extraction technique should be virtually exhaustive. Recent developments of sample handling techniques are directed, from one side, toward automatization and online coupling of sample preparation units. The primary objective of this review is to present the recent developments in microextraction sample preparation methods for analysis of drugs in biological fluids. Microextraction techniques allow for less consumption of solvent, reagents, and packing materials, and small sample volumes can be used. In this review the use of solid phase microextraction (SPME), microextraction in packed sorbent (MEPS), and stir-bar sorbtive extraction (SBSE) in drug analysis will be discussed. In addition, the use of new sorbents such as monoliths and molecularly imprinted polymers will be presented.Entities:
Year: 2014 PMID: 24688797 PMCID: PMC3943203 DOI: 10.1155/2014/921350
Source DB: PubMed Journal: J Anal Methods Chem ISSN: 2090-8873 Impact factor: 2.193
Figure 1Construction of automated in-tube SPME-HPLC/MS system and Scanning electron microscope images of the cross section of the hybrid silica monolith: wide view (b) and close-up view (c) [74].
Figure 2Scheme of the operation mode of the six-port switching valve in the RAM in-tube SPME developed method [76].
Figure 3Schematic illustration of MIP preparation procedure [78].
Figure 4Schematic of (a) the formation of polydopamine layer and (b) modification of PEEK tube and preparation of poly(AA-EGDMA) monolith and Scanning electron micrograph of (A) polydopamine layer on the inner wall of PEEK tube, (B) poly(AA-EGDMA) monolith, and (C) interface of inner wall of PEEK tube and polymer monolith [79].
HSPME for analysis of different drug components.
| Drug | Disease | Fiber type | Sample matrix | Analytical method | Reference |
|---|---|---|---|---|---|
| Dichlorobenzene | Damage to the liver and the kidneys | Polydimethylsiloxane | Human blood | GC/MS | [ |
| Illegal drugs (acetylated amphetamine, secobarbital, phenobarbital, methadone, propoxyphene, imipramine, acetylated codeine, flunitrazepam, diacetylated morphine) | Polyacrylate | (In situ) derivatisation | Urine/serum | GC/MS | [ |
| Thymol | Food/pharmaceuticals | Polydimethylsiloxane- | Human plasma | GC/MS | [ |
| Amphetamine-related drugs | Abused drugs | Polydimethylsiloxane | Human urine | GC/MS | [ |
| Rivastigmine | Symptomatic treatment of | Polydimethylsiloxane/divinylbenzene | Canine plasma | GC/MS | [ |
| Menthol | Flavouring agent | 65 µm polydimethylsiloxane/divinylbenzene (PDMS/DVB)-coated fibers | Plasma/urine of rats | GC/MS | [ |
| Ephedrine, methamphetamine | Anaesthesia | Sol-gel | Human urine | GC | [ |
| Asarones | Antiepileptic drugs | Polydimethylsiloxane (PDMS), 65 | Plasma | GC/MS | [ |
| Paeonol | Eczema | 100 µm polydimethylsiloxane (PDMS), 65 | Rabbit plasma /essential oil | GC/MS | [ |
| Fentanyl | Surgical analgesia and sedation | Sol-gel technology | Human plasma | GC/MS | [ |
| Diisopropylfluorophosphate | Miotic agent in treatment of chronic glaucoma | 65 mm polydimethylsiloxane/divinylbenzene | Rat plasma/brain tissue | GC/MS | [ |
| Some phenothiazine derivatives | Antipsychotics | 100 | Human blood | GC/NPD | [ |
| Methadone | Analgesic | Nanostructured a-carboxy | Plasma/urine | GC/FID | [ |
| Ethyl glucuronide | Promising biomarker of heavy prenatal alcohol exposure | 100 | Human placenta | GC/MS | [ |
| Ranitidine | Prescribed | Carboxen/polydimethylsiloxane | Solid state | GC/MS | [ |
| Volatile organic metabolites | volatile organic metabolites | Pdms, pdms/dvb, cw/dvb, | Mentha ×piperita L | GC/qMS | [ |
|
| Antimicrobial agents | For example, 100 | Cell metabolism | GC/MS | [ |
Figure 5SPME high-temperature headspace sampling [88].
Function and chemical structures of the coating solution ingredients for sol-gel-derived DM-β-CD/OH-TSO coating [34].
|
|
Figure 6The chemical structure of the DM-β-CD/OH-TSO coating [34].
Figure 7Preparation of molecularly imprinted fiber [91].
Figure 8Schematic representation of in-tube MIP SPME configuration. (a) Load position (extraction); (b) injection position (desorption) [92].
Figure 9The preparation process of BPA-imprinted MIP coating on the silylated wall of the silica capillaries. Schematic representation of BPA-imprinted MIP coating on the silylated wall of the silica capillaries and Scanning electron micrographs of MIP coating of the fiber. (a) ×200, (b) ×20000 [97].
Figure 10Chemical reactions involved in the synthesis of surface-bonded sol-gel hybrid organic-inorganic polymeric network [107].
Figure 11Schematic diagrams of the preparation of MIP-SBSE coating using terbuthylazine as template molecule and Scanning electron micrographs of the surface structure of the MIP- and NIP-coated stir-bar. (a) and (c) are the NIP coating for magnitude of 100 and 5000, respectively, (b) and (d) are the MIP coating for magnitude of 100 and 5000, respectively [114].
Figure 12Photograph of different dimensions of SBSEM [118].
Figure 13MEPS syringe with sorbent.
Extraction of different analytes by MEPS technique.
| Components | Sample matrix | MEPS sorbent | References |
|---|---|---|---|
| Methadone | Human urine | Silica-C8 | [ |
| Dopamine/serotonin | Human urine | Silica-C8 | [ |
| Cocaine/metabolites | Human urine | Silica-C8 | [ |
| Clozapine/metabolites | Dried blood spots | Silica-C8 | [ |
| Methadone/buprenorphine/norbuprenorphine/naloxone | Plasma | Silica-C8 | [ |
| Pravastatin/pravastatin lactone | Rat plasma/urine | Silica-C8 | [ |
| Immunosuppressive drugs (Cyclosporine, everolimus, | Whole blood | Silica-C8 | [ |
| Oxcarbazepine/metabolites | Plasma/saliva | Silica-C18 | [ |
| Antiepileptic drugs | Human plasma/urine | Silica-C18 | [ |
| Amiodarone/desethylamiodarone | Human plasma | Silica-C18 | [ |
| Methadone | Dried blood spots | Silica-C18 | [ |
| Biogenic amines | Human urine | Silica-C18 | [ |
| Metabolites of monoterpenes | Human urine | C18/silica phases | [ |
| Acebutolol, metoprolol | Human plasma/urine | Polystyrene polymer | [ |
| Busulphan | Human plasma | Polystyrene polymer | [ |
| Linezolid and amoxicillin | Human plasma | (C2, C8, C18, M1 (80% C8 and 20% SCX), and Sil (pure silicate)) | [ |
| Cotinine | Human urine | (C2, C8, C18, silica, and C8/SCX) | [ |
| Psychotropic drugs | Human serum | C18, C8, and C8-SCX | [ |
| Antipsychotic drugs | Human plasma | 80% C8 and 20% SCX | [ |
| Local anaesthetics | Human plasma | Benzenesulphonic acid cation exchange silica | [ |
| Ropivacaine /metabolites | Human urine | Polystyrene polymer, ISOLUTE ENV+ | [ |
| Lidocaine, glycylxylidide (GX), monothylglycylxylidide (MEGX), and 3-OH lidocaine | Human plasma/urine | Silica based (C8), polymer based (ENV+), and a methacrylate based organic monolith | [ |
| Antidepressants | Human plasma | C8/strong cationic exchange | [ |
| Ropivacaine | Human plasma | Methylcyanopropyl/silarylene (50/50) | [ |
| Ropivacaine, lidocaine, bupivacaine, mepivacaine | Human plasma | Molecularly imprinted polymers (mips) | [ |
| Cyclophosphamide | Human plasma | C2-sorbent | [ |
| Codeine metabolites | Human urine | Barrel insert needle (BIN), poly(styrene co-divinylbenzene) | [ |
| Propranolol, metoprolol, verapamil | Human urine | C2, C8, C18, M1 (cation exchanger), and Sil (pure silica) | [ |
| Bam peptide | Human plasma | C8 | [ |
Figure 14Monolithic packed 96-tips.
Applications of monolithic methacrylate polymer packed 96-tip.
| Compound class/compound | Sample matrix | Sample volume ( | Analytical method | Calibration range | References |
|---|---|---|---|---|---|
| Local anaesthetics | |||||
| Lidocaine | Human plasma | 100 | LC-MS/MS | 14–5000 nM | [ |
| Ropivacaine | Human plasma | 100 | LC-MS/MS | 2–2000 nM | [ |
| Bupivacaine | Human plasma | 100 | LC-MS/MS | 2–2000 nM | [ |
| Anticancer drugs | |||||
| Cyclophosphamide | Mice blood | 20 | LC-MS/MS | 10–2000 nM | [ |
| Busulphan | Human blood | 100 | LC-MS | 5–2000 nM | [ |
| Roscovitine | Human plasma | 100 | LC-MS/MS | 14–5000 nM | [ |
|
| |||||
| Pindolol | Human plasma | 100 | LC-MS/MS | 0.5–5000 nM | [ |
| Metoprolol | Human plasma | 100 | LC-MS/MS | 0.5–5000 nM | [ |